Table 3 Levels of LecT-Hepa, FIB-4 and APRI in45 CHC patients during 48 weeks course of IFN therapy

−9.22 ± 3.77

−9.09 ± 4.66

−8.72 ± 5.66

−8.71 ± 4.69

−8.98 ± 4.88

−2.10 ± 4.63

−2.14 ± 5.02

−2.12 ± 4.72

−3.47 ± 5.13

−4.40 ± 5.01

0.83 ± 5.06

2.82 ± 5.60

2.38 ± 5.32

1.29 ± 4.39

−0.17

−4.69 ± 6.11

−3.25 ± 7.01

−3.24 ± 6.97

−4.19 ± 6.21

−7.31 ± 5.35

1.63 ± 1.06

1.72 ± 0.70

2.03 ± 0.94

1.87 ± 1.03

1.81 ± 0.68

4.17 ± 3.11

2.79 ± 2.17

3.33 ± 2.49

2.91 ± 1.61

2.84 ± 0.91

4.57 ± 2.71

3.80 ± 1.95

4.35 ± 1.91

3.94 ± 1.53

4.55

3.27 ± 2.68

2.70 ± 1.85

3.15 ± 2.04

2.79 ± 1.60

2.22 ± 1.01

0.96 ± 1.11

0.54 ± 0.27

0.58 ± 0.36

0.51 ± 0.29

0.66 ± 0.76

2.44 ± 2.18

0.70 ± 0.32

0.76 ± 0.37

0.82 ± 0.56

0.89 ± 0.48

2.92 ± 3.15

1.26 ± 0.61

1.19 ± 0.45

1.10 ± 0.46

1.44

1.98 ± 2.31

0.81 ± 0.52

0.83 ± 0.46

0.78 ± 0.49

0.76 ± 0.69